Serial measurement of galectin‐3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. (October 2013)

• Record Type: Journal Article
• Authors: Motiwala, Shweta R.; Szymonifka, Jackie; Belcher, Arianna; Weiner, Rory B.; Baggish, Aaron L.; Sluss, Patrick; Gaggin, Hanna K.; Bhardwaj, Anju; Januzzi, James L.
• Is Part Of: European journal of heart failure. Volume 15:Number 10(2013)
• Page Start: 1157
• Page End: 1163
• Publication Date: 2013-10
• Subjects: Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1093/eurjhf/hft075
• Languages: English
• ISSNs: 1388-9842

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ejhfhft075-sec-0001" sec-type="section"> <title>Aims</title> <p>Galectin‐3 is a prognostic heart failure (HF) biomarker that may mediate cardiac fibrosis. We examined the value of serial galectin‐3 measurement for prognosis and response to therapy in chronic HF.</p> </sec> <sec id="ejhfhft075-sec-0002" sec-type="section"> <title>Methods and results</title> <p>A total of 151 subjects with LV systolic dysfunction (LVSD) were followed through 908 visits over 10 ± 3 months. The amount of time spent with a galectin‐3 level ≤ 20.0 ng/mL and changes between baseline and subsequent values were considered across visits, and used to assess risk for adverse cardiovascular (CV) events and associations with LV remodelling. Medication effects on galectin‐3 were examined. Median galectin‐3 values at baseline, 3 months, and 6 months were higher in patients with CV events (21.7 vs. 18.4 ng/mL, <italic>P</italic> = 0.03; 21.7 vs. 16.5 ng/mL, <italic>P</italic> = 0.03; 23.2 vs. 16.0 ng/mL, <italic>P</italic> = 0.007). Galectin‐3 concentration changed in 35.2% of subjects during study procedures; time spent at ≤ 20.0 ng/mL was significantly associated with a lower rate of CV events, independently predicted fewer CV events even adjusted for relevant variables including study allocation, NT‐proBNP, and renal function [odds ratio (OR) = 0.90; <italic>P</italic> = 0.05], and predicted increase in LV ejection fraction (OR = 1.20; <italic>P</italic> = 0.04). Serial galectin‐3 measurement at 6 months added prognostic value beyond the baseline level (<italic>P</italic> = 0.02). There were no significant effects of medications on galectin‐3 levels.</p> </sec> <sec id="ejhfhft075-sec-0003" sec-type="section"> <title>Conclusion</title> <p>In chronic HF due to LVSD, serial galectin‐3 measurement adds incremental prognostic information and predicts LV remodelling. In this study, HF therapies had no clear effects on galectin‐3 levels.</p> </sec> </abstract>